Rasha Aboelhassan: MDT is the cornerstone for treatment decisions, especially for HCC patients
Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn:
“MDT is the cornerstone for treatment decisions, especially for HCC patients who have more than cancer, HCC patients have liver cirrhosis, hepatitis which may be active, as well as other comorbidities.
While immunotherapy regimes can never fit for all HCC patients, yesterday, we had a weekend different HCC MDT to discuss.
‘5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC’.
This was the first step to giving MDT a new role for solving debates, discussing clinical trials just for patients benefits.”
More posts featuring Rasha Aboelhassan.
Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field and is in the Editorial Staff of Egyptian Journal of Human Genetics. Rasha has been accepted as a member of staging and Prognostic Factors Group of lung cancer SPFG.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023